A. Khurana PhD (Amit)

I am a graduate in pharmacy (B.Pharm.) from Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), University of Delhi. I received my M.S. (Pharm.) degree in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India, in 2014. In the same year, I began Ph.D. work as a NIPER fellow at NIPER, Hyderabad, India (2014-20). In 2017, I received a fellowship from the DST (India) and DAAD (Germany) to work on a liver targeting formulation for the therapy of liver fibrosis (RWTH Aachen, Aachen, Germany). Further, I worked as a DBT-CNPq research fellow in an Indo-Brazil collaborative project (2016-19, University of Sau Paulo, Brazil). For my PhD thesis, I worked on novel therapeutics for the treatment of acute and chronic pancreatitis. Currently, as a DAAD-PRIME Fellow I am exploring the role of lipoxygenase enzymes for pharmacological targeting of non-alcoholic steatohepatitis (NASH).

Medicine & Life Sciences

# Chronic Disease
# Lipoxygenases
# Liver Diseases

Engineering & Materials Science

# Medical Problems
# Nanoparticles
# Polysaccharides

Chemistry

# Disorder
# Polysaccharide

Faculty of Science and Technology (TNW), Medical Cell Biophysics (MCBP)

Currently, I focus on mechanistic targeting of non-alcoholic steatohepatitis (NASH). NASH is the leading cause of liver transplantation and the pathological mechanisms of NASH remain still elusive. In this project, I am studying the pathological role of the lipoxygenase (LOX) enzymes in the progression of NASH. This project is a unique collaboration combining fundamental liver research (with Prof. Ralf Weiskirchen, RWTH University Hospital, Aachen, Germany) and translational liver targeting research (With Prof. Ruchi Bansal, at MCBP-TLR, UT) contributing towards improved understanding of disease pathogenesis and a novel therapeutic for the treatment of NASH.

Heinrich, L. , Booijink, R. S. , Khurana, A. , & Bansal, R. (2022). Lipoxygenases in chronic liver diseases: current insights and future perspectives. Trends in pharmacological sciences, 43(3), 188-205. https://doi.org/10.1016/j.tips.2021.12.001

Allawadhi, P., Singh, V. , Govindaraj, K., Khurana, I., Sarode, L. P., Navik, U., Banothu, A. K., Weiskirchen, R., Bharani, K. K. , & Khurana, A. (2022). Biomedical applications of polysaccharide nanoparticles for chronic inflammatory disorders: Focus on rheumatoid arthritis, diabetes and organ fibrosis. Carbohydrate polymers, 281, [118923]. https://doi.org/10.1016/j.carbpol.2021.118923

See all research output of this employee

View my profile

1. Ph.D in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India (2020).

2. M.S. (Pharm.) in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Punjab, India (2014).

3. B. Pharmacy from the Delhi Institute of Pharmaceutical Sciences and Research, University of Delhi, New Delhi, India (2012).

+31534898221

+4915175336947 (mobile)

+918019945490 (if no answer)

a.khurana@utwente.nl

ak3.khurana@gmail.com